Journal News

From the journals: MCP

Elisabeth Adkins Marnik
Feb. 2, 2024

Are proteomics helping to detect ovarian cancer? The challenges and promises of biomarkers. New technique helps detect protease cleavage. Read about papers on these topics recently published in the journal Molecular & Cellular Proteomics.

 

Are proteomics helping to detect ovarian cancer?

Epithelial ovarian cancers, or EOCs, make up about 90% of all ovarian cancers. EOC originates in the surface layer covering the ovary and then spreads. When diagnosed early, EOC has about a 93% five-year survival rate. Early diagnosis is rare; however, due to a lack of specific symptoms. Many patients are not diagnosed until the cancer has significantly progressed, which decreases the five-year survival rate to 50%.

High-grade serous ovarian cancer accounts for approximately 75%25 of cases of epithelial ovarian cancer.
High-grade serous ovarian cancer accounts for approximately 75% of cases of epithelial ovarian cancer.

The five histological subtypes of EOC are low-grade serous ovarian carcinoma, mucinous carcinoma, endometrioid carcinoma, clear cell carcinoma and high-grade serous ovarian cancer. This last is the most aggressive and prevalent form, making up 75% of diagnosed ovarian cancers. Each subtype has different molecular underpinnings and all have varying treatment success rates. Researchers seek to identify biomarkers to facilitate early EOC diagnosis and enhance treatment options.

In a recent article published in the journal Molecular & Cellular Proteomics, Liujia Qian and colleagues from Westlake University in China performed a systematic review of over 2,500 ovarian cancer clinical trials to assess progress in the discovery of EOC biomarkers and therapeutic targets as well as the translation of these findings to clinical use.

EOC proteomics research relies on detecting biomarkers in serum and plasma where they are easily obtained, the authors explain. Researchers then use algorithms to predict the likelihood of ovarian cancer or its progression in patients based on the presence of the biomarkers. Some of these tests are already being used in the clinic, but others remain under-studied.

Some researchers also use samples directly from ovarian tumors or adjacent tissues to identify dysregulated proteins in EOC. When the Westlake team reviewed clinical data, they found that none of the current leading therapeutic targets were discovered from these methods, although some are in clinical trials.

So, while proteomics has not yet led to therapeutics, researchers hope that as the field and technology progress, so will options for patients with EOC.

 

The challenges and promises of biomarkers

Biomarkers, typically proteins detected in patients’ blood or tissue, hold significant potential to help clinicians practice medicine more effectively. They can be used to diagnose and monitor disease progression, identify targets for drug development, monitor treatment effectiveness and predict which patients are at risk for drug side effects. Despite the promise of their utility, however, researchers have seen limited success and faced many challenges in bringing biomarkers to the clinic.

In a recent article in the journal Molecular & Cellular Proteomics, Jakob Bader and colleagues at the Max Planck Institute described challenges, technological advancements and success stories related to using mass spectrometry to identify biomarkers from body fluid samples. Many of the challenges were due to technological difficulties in high-throughput sample processing.

Researchers now address many of the challenges of biomarker discovery by using automation and simplified and improved protocols. Due to the many technological improvements the authors outline, it is possible to use larger cohorts of patients for better biomarker identification. This could mean the future is here, and with it, hopefully, the discovery of better biomarkers.

 

New technique helps detect protease cleavage

Proteases are enzymes responsible for cleaving proteins into smaller polypeptide chains or individual amino acids. This cleaving can modulate specific proteins and regulate key cellular processes. One such process is apoptosis, a form of programmed cell death, where various proteases are instrumental in initiating the breakdown of cellular protein components.

Proteases are important enzymes, and researchers need to be able to catalog their targets when studying the proteome. However, using mass spectrometry, or MS, to identify protein fragments generated by proteases is difficult.

To address this, Rawad Hanna and colleagues at the Technion–Israel Institute of Technology developed a new technique called LysN amino terminal enrichment, or LATE. This technique combines digestion with LysN and isotope labeling of the N-terminal end of a protein to better identify cleaved proteins in MS analysis.

The researchers recently described this work in the journal Molecular & Cellular Proteomics. By using LATE, they were able to identify novel targets of cleavage by caspase-3, a protease involved in apoptosis. They also discovered cross-talk between caspase-3 cleavage and N-terminal acetylation.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Elisabeth Adkins Marnik

Elisabeth Adkins Marnik is the Director of Science Education & Outreach at the MDI Biological Laboratory in Bar Harbor, Maine, where she is spearheading the development of new programming. This work is driven by her passion for making science accessible to students and the public. She is an ASBMB Today volunteer contributor as well as the Chief Scientific Officer of Those Nerdy Girls. Follow her on Instagram @sciencewhizliz.
 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Antibiotic sensor directly binds drug in resistant bacteria
Journal News

Antibiotic sensor directly binds drug in resistant bacteria

Oct. 8, 2025

Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.

ApoA1 reduce atherosclerotic plaques via cell death pathway
Journal News

ApoA1 reduce atherosclerotic plaques via cell death pathway

Oct. 1, 2025

Researchers show that ApoA1, a key HDL protein, helps reduce plaque and necrotic core formation in atherosclerosis by modulating Bim-driven macrophage death. The findings reveal new insights into how ApoA1 protects against heart disease.

Omega-3 lowers inflammation, blood pressure in obese adults
Journal News

Omega-3 lowers inflammation, blood pressure in obese adults

Oct. 1, 2025

A randomized study shows omega-3 supplements reduce proinflammatory chemokines and lower blood pressure in obese adults, furthering the understanding of how to modulate cardiovascular disease risk.

AI unlocks the hidden grammar of gene regulation
Feature

AI unlocks the hidden grammar of gene regulation

Sept. 30, 2025

Using fruit flies and artificial intelligence, Julia Zeitlinger’s lab is decoding genome patterns — revealing how transcription factors and nucleosomes control gene expression, pushing biology toward faster, more precise discoveries.

Zebrafish model links low omega-3s to eye abnormalities
Journal News

Zebrafish model links low omega-3s to eye abnormalities

Sept. 24, 2025

Researchers at the University of Colorado Anschutz developed a zebrafish model to show that low maternal docosahexaenoic acid can disrupt embryo eye development and immune gene expression, offering a tool to study nutrition in neurodevelopment.

Top reviewers at ASBMB journals
Observance

Top reviewers at ASBMB journals

Sept. 19, 2025

Editors recognize the heavy-lifters and rising stars during Peer Review Week.